Merck

RANK71

Pharmaceutical company Merck fell six spots on the list in its first year with CEO Robert Davis at the helm. But that modest slide masks a successful year in which profits jumped 85%, to $13 billion. Excluding revenue from Organon, the women’s health company whose spinoff was completed in June 2021, Merck’s sales overall increased 17%, including a 20% gain for the company’s hallmark cancer drug Keytruda and a 44% increase in sales for HPV vaccine Gardasil. Merck also registered nearly $1 billion in sales for molnupiravir, an oral antiviral treatment for COVID that received emergency use authorization from the FDA in December 2021.